NCT01397422 - Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

October 31, 2013

Conditions

DyskinesiaLevodopa Induced DyskinesiaParkinson's Disease

Interventions

DRUG

ADS-5102 (extended release amantadine HCl)

Oral capsules to be administered once daily at bedtime, for 8 weeks

Trial Locations (33)

Unknown

Sun City

Fountain Valley

Long Beach

Los Angeles

Oxnard

Pasadena

Reseda

Sunnyvale

Ventura

Fairfield

Boca Raton

Bradenton

Port Charlotte

Tampa

Atlanta

Augusta

Chicago

Winfield

Des Moines

Kansas City

Boston

West Bloomfield

Toms River

New York

Durham

Raleigh

Toledo

Tulsa

Houston

San Antonio

Richmond

Kirkland

Milwaukee